Lam Research Corporation vs NVIDIA Corporation — Stock Comparison
Q·Score Breakdown
8.6
Strong Buy
Overall
9.1
Strong Buy
Quality
Health
Growth
Valuation
Sentiment
LRCX
Earnings growing 41% year-over-year on 24% revenue growth.
NVDA
Clean balance sheet with low leverage (0.1× debt-to-equity).
Analyst Consensus
BUY
Target $307.74 (+20.6%)
31 analysts
BUY
Target $269.17 (+34.2%)
57 analysts
Fundamentals
LRCX
NVDA
48.1×
Trailing P/E
40.9×
32.6×
Forward P/E
17.8×
30.9%
Profit Margin
55.6%
50.0%
Gross Margin
71.1%
66.8%
ROE
101.5%
23.8%
Revenue Growth
73.2%
40.8%
Earnings Growth
95.6%
1.79
Beta
2.33
—
Price / Book
—
$319.1B
Market Cap
$4.87T
$71 – $276
52-Week Range
$111 – $217
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.